

2022 - 1

Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB-506 from Phase 1 studies in healthy subjects and those with hepatitis B

Yuen Man-Fung¹, Berliba Elina², Sukeepaisarnjaroen Wattana³, Ahn Sang Hoon⁴, Tanwandee Tawesak⁵, Lim Young-Suk⁶, Kim Yoon Jun⁷, Poovorawan Kittiyod⁵, Tangkijvanich Pisit⁸, Schwabe Christian⁹, Eley Timothy¹⁰, Brown Joanne¹⁰, Noi Autori¹, Gane Edward John¹¹

¹ University of Hong Kong, Hong Kong,

² F.C.E. ARENSIA Exploratory Medicine,

³ Khon Kaen University,

⁴ Yonsei University, Seoul,

⁵ Mahidol University, Bangkok,

⁶ Asan Medical Center, Seoul,

⁷ Seoul National University,

⁸ Chulalongkorn University,

⁹ Auckland Clinical Studies, Auckland,

¹⁰ Arbutus Biopharma, Warminster,

¹¹ University of Auckland

Hepatology Communications

Vol. 6, / 2022 / ISSN 2471-254X

Disponibil online 12 September, 2023. Descarcări-4. Vizualizări-231



Copyright © 2011-2024 Instrumentul Bibliometric Național.

Institutul de Dezvoltare a Societății Informaționale.

Actualizat: 21.05.2024, accesat: 21.05.2024

Disponibil: <https://ibn.idsi.md>

